Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 13/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumatriptan SCHEMBL183393 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL29450235 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1421675 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL4916383 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1503483 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL29657591 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6688549 | 0.94 | HTR1A (0.89) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6689001 | 0.93 | HTR1A (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL29355619 | 0.93 | HTR1D (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL2404748 | 0.92 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31611 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4749653-A2 | DRUG DELIVERY DEVICES WITH REUSABLE COMPONENTS AND DISPOSABLE COMPONENTS | Janssen Pharmaceutica NV (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4208222-B1 | DRUG SYRINGES WITH A MECHANICAL STOP FOR A SECOND DOSE | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-06 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4208234-B1 | DRUG DELIVERY DEVICES WITH MULTIPLE DRUG VIALS | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-08 | — | — | EP | claimed |
| US-5137516-A | TRIGGERED APPLICATION DEVICE FOR MEDICAMENT TO BE MORE DESCRIPTIVE OF THE INVENTION | GLAXO GROUP LIMITED (GB) | 1992-08-11 | — | — | US | claimed |
| WO-1992012713-A1 | COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1992-08-06 | — | — | WO | claimed |
| WO-1992012712-A1 | COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1992-08-06 | — | — | WO | claimed |
| EP-0496308-A1 | Intranasal compositions comprising 3-[2-(dimethylamino) ethyl]-N-methyl-1H-indole-5-methynesulphonamide | GLAXO GROUP LIMITED (GB) | 1992-07-29 | — | — | EP | claimed |
| EP-0496307-A1 | Compositions for intranasal administration comprising sumatriptan | GLAXO GROUP LIMITED (GB) | 1992-07-29 | — | — | EP | claimed |
| WO-1992011003-A1 | PHARMACEUTICAL COMPOSITIONS | LABORATOIRES GLAXO S.A. (FR) | 1992-07-09 | — | — | WO | claimed |
| WO-1992010477-A1 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1992-06-25 | — | — | WO | claimed |
| EP-0490689-A1 | 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate (2:1) | GLAXO GROUP LIMITED (GB) | 1992-06-17 | — | — | EP | claimed |
| WO-1992000103-A1 | PHARMACEUTICAL PREPARATIONS | BEECHAM GROUP PLC (GB) | 1992-01-09 | — | — | WO | claimed |
| EP-0433043-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 1991-06-19 | — | — | EP | claimed |